# A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

> **NCT01638676** · PHASE1,PHASE2 · RECRUITING · sponsor: **University of Louisville** · enrollment: 55 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** Vemurafenib
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT01638676
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2012-07
- **Primary completion:** 2025-06
- **Final completion:** 2027-06
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2021-10-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01638676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01638676, "A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01638676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*